New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- Hyperlipidemia
Icosapent ethyl in post-CABG patients with diabetes
Subodh Verma, MD, PhD
- Hyperlipidemia
Phase 3 study results of plozasiran in patients with FCS
Gerald F. Watts, DSc, DM, PhD
- ESC Congress 2024
New ESC Guidelines for CCS and PAAD
Pierre Sabouret, MD, PhD
- ESC Congress 2024
Intensive and early lowering of atherogenic lipids after MI
Jessica Schubert, MD